🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 62818Q203 (prev. 62818Q104 )
- Market Cap
- Micro Cap
Business: Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market.
Notes: April 03, 2023 -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that it will effect a 15-for-1 reverse stock split of its issued and outstanding common stock. Mustang expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on April 4, 2023. Mustang’s common stock will continue to trade on the Nasdaq Capital Market under the symbol “MBIO” following the reverse stock split, with a new CUSIP number of 62818Q203.
Company Contact
- CEO
- Manuel Litchman
- CFO
- James Murphy
- Headquarters
- 377 Plantation Street, Worcester, MA 01605
- Phone
- 781-652-4500
- Investor Relations
- Daniel Ferry, LifeSci Advisors LLC · 617-430-7576 · daniel@lifesciadvisors.com